Correction to Figure 1 in the PANORAMA Trial Report on Intravitreal Aflibercept for Severe Nonproliferative Diabetic Retinopathy
-
October 1, 2026
Clinical Scorecard: Correction to Figure 1 in the PANORAMA Trial Report on Intravitreal Aflibercept for Severe Nonproliferative Diabetic Retinopathy
At a Glance
| Category | Detail |
|---|---|
| Condition | Severe nonproliferative diabetic retinopathy |
| Key Mechanisms | The correction concerns a trial report of intravitreal aflibercept; the source does not describe disease mechanisms. |
| Target Population | Not specified in the correction notice. |
| Care Setting | Clinical trial research on intravitreal aflibercept for severe nonproliferative diabetic retinopathy. |
Key Highlights
- The PANORAMA Randomized Clinical Trial report underwent an online correction.
- The correction addressed numerical inconsistencies in Figure 1.
- A Results time point was specified more clearly.
- A typographical error in eTable 3 of Supplement 2 was corrected.
- The article was initially posted on August 5, 2021, later appeared in the September issue, and was corrected online.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
The trial report concerns severe nonproliferative diabetic retinopathy; the correction notice provides no further patient-population details.
The report concerns intravitreal aflibercept. The correction notice does not provide dosing, efficacy, or safety information.
Clinical Best Practices
Related Resources & Content
Based on findings from:
Error in Figure 1
Jama Ophthalmology, 2026.
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2852986
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
